Abstract 1865P
Background
This study aimed to determine how the chemotherapy process can lead to a change in self-esteem in elderly patients with early-stage breast cancer according to personality type.
Methods
The research was completed as a pilot study between 2019-2022. Female patients aged 65 and over who were planned for adjuvant treatment were included in the study. Personality type and self-esteem were determined in all patients before and after adjuvant chemotherapy. Bortner Rating Scale was used to determine personality type, and Rosenberg Self-Esteem Scale was used to determine self-confidence. Paired t-test was performed for recurrent variables in pre-treatment and post-treatment measures. Multivariate logistic (binary) regression analysis was performed to determine the independent factors affecting low self-esteem from the study variables with the model created as a result of correlation and univariate analysis. Statistical analysis was performed using the SPSS v19 program and a p value of <0.05 was considered statistically significant.
Results
A total of 69 Her2-negative elderly female patients were included in this pilot study. The mean age of the patients was 68 years (65-72). 54% had radical mastectomy. 69% received paclitaxel for 12 weeks, 21% received 6x DC, and 10% received 3x CEF followed by 3x docetaxel for adjuvant setting. 56% of them had personality type A. Before treatment, 62% had high self-esteem and this was significantly higher in type A personality than in type B (84% vs 48%, respectively; p=0.037). While the rate of high self-esteem decreased in type A personality after treatment (p=0.009), there was no change in type B personality (p=0.379). It was determined that type A personality structure was independent affecting low self-esteem after treatment (OR 5.37 95%CI 1.489-9.396; p=0.006).
Conclusions
In this study, it was concluded that elderly women with type A personality structure may be more sensitive and may have low self-esteem after the treatment is completed. It was concluded that the personality type should be guided by the patient's treatment compliance, need for psychosocial support, and coping methods after the completion of the treatment, supported by the physician.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics committee approval could not be obtained because it was a pilot study. In the follow-up research, the results of the pilot study will be declared and consent will be obtained.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05